EMCDDA Home
  • EN
Search

Table TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2011 or most recent year available

Part (vi) All volatile inhalant outpatient clients by country and age at first use

Country<1515-1920-2425-2930-3435-3940-4445+Age knownAge not knownTotal
Belgium01000000189
Bulgaria03112000729
Czech Republic13100000505
Denmark03101000527
Germany14101132100411657
Estonia5::::::::::
Ireland15220000019120
Greece20000100303
Spain12119101002442872
France28167:1:1::30:
Italy20700800015015
Cyprus00000000000
Latvia35415000000691382
Lithuania:::::::::::
Luxembourg:::::::::::
Hungary71402000023023
Malta21:::::::::
Netherlands111001004812
Austria01000000101
Poland41::::::::::
Portugal510000000101
Romania10100000202
Slovenia:::::::::::
Slovakia91020000021021
Finland01000000101
Sweden10000000101
United Kingdom619982123621::33:
Croatia1100000::0:
Turkey:::::::::::
Norway00000000000
Total36319040921522263141341
 

Notes:

: Indicates no data are available

(1) Data are from 2010.

(2) In 2011 around 27% of all clients and 32% of new clients were registered as not known / missing for the primary drug category. Caution should be made when comparing data over time.

(3) In 2010 Latvia submitted a new dataset with a more precise TDI EMCDDA definition. Caution should be made when comparing data with previous years.

(4) Data are from 2010. Data presented in the table come from TDI pilot project. Caution should be made when interpreting the data.

(5) In 2010 came into implementation a new national information system implying methodological changes particularly in the registration criteria. Caution should be made when comparing 2010 data with previous years.

(6) Data are from 1st of April 2010 to 31st March 2011.

For more information relative to the treatment centre type, please see Table TDI-7.

See also Table TDI-11 part(i), part(ii)

‘General notes for interpreting data'’ on the Explanatory notes and help page.

Source:

Reitox national reports 2012- Table TDI Outpatient Treatment Centres

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
Fax (351) 218 13 17 11

More contact options >>

Page last updated: Friday, 26 April 2013